EcoDrugPlus

Fibroblast Growth Factor Receptor 1-A-Like

Ensembl ID : ENSAPOG00000002758
Gene Symbol: LOC110964131
4 Cross references
208 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSAPOG00000004708
Gene Symbol: FGFR2
3 Cross references
217 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSAPOG00000015273
Gene Symbol: LOC110959711
3 Cross references
191 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSAPOG00000024197
Gene Symbol: FLT1
3 Cross references
199 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSAPOG00000015895
Gene Symbol: FLT4
3 Cross references
197 Possible Orthologues:

Folate Receptor Alpha-Like

Ensembl ID : ENSAPOG00000002212
Gene Symbol: LOC110955307
3 Cross references
436 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSAPOG00000024214
Gene Symbol: LOC110958812
2 Cross references
340 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSAPOG00000017367
Gene Symbol: FRK
3 Cross references
217 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSAPOG00000013392
Gene Symbol: GLA
3 Cross references
197 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSAPOG00000017325
Gene Symbol: LOC110953226
3 Cross references
220 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1-Like

Ensembl ID : ENSAPOG00000005352
Gene Symbol: LOC110959328
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-2-Like

Ensembl ID : ENSAPOG00000010995
Gene Symbol: LOC110964550
2 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).